Biovica: Preparing to activate US channels for clinical use of DiviTum - Redeye

Biovica records SEK 2.6m in total net sales (51% above Q1 last year), and clinical sales increased by 72%. Biovica is working together with the US partner Tempus, and the next stage is to roll out DiviTum over the coming quarters. Bioivca delivers high growth from a very modest base, and the challenge for the rest of 2025/26 is to provide a significant absolute increase, allowing Bioivca to progress towards break-even the following year.

Länk till analysen i sin helhet: https://www.redeye.se/research/1127353/biovica-preparing-to-activate-us-channels-for-clinical-use-of-divitum?utm_source=finwire&utm_medium=RSS